Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Clin Colorectal Cancer. 2018 Feb 27;17(2):e395–e414. doi: 10.1016/j.clcc.2018.02.010

Table 1.

Association Between Gene Polymorphism and Clinical Outcome

N Disease Control Progression-Free Survival Overall Survival
PR + SD PD P value* Median (95% CI), mo Univariate HR (95% CI) P value* Multivariable HR (95% CI) P value* Median (95% CI), mo Univariate HR (95% CI) P value* Multivariable HR (95% CI) P value*
CCL5 rs2280789 .42 .56 .21 .36 .039
 A/A 27 13 (59%) 9 (41%) 2.3 (1.8, 3.3) 1 (Reference) 1 (Reference) 7.9 (4.0, 29.9) 1 (Reference) 1 (Reference)
 A/G 35 12 (46%) 14 (54%) 2.0 (1.5, 2.5) 1.01 (0.61, 1.69) 1.20 (0.72, 2.02) 8.1 (4.6, 12.6) 1.19 (0.64, 2.22) 1.53 (0.81, 2.91)
 G/G 17 6 (38%) 10 (63%) 2.0 (1.7, 4.7) 0.76 (0.41, 1.43) 0.68 (0.36, 1.30) 12.9 (5.0, 27.7) 0.71 (0.32, 1.57) 0.56 (0.25, 1.27)
.39 .28 .11 .19 .032
 Any A 62 25 (52%) 23 (48%) 2.0 (1.8, 2.7) 1 (Reference) 1 (Reference) 7.9 (5.8, 11.8) 1 (Reference) 1 (Reference)
 G/G 17 6 (38%) 10 (63%) 2.0 (1.7, 4.7) 0.76 (0.43, 1.32) 0.62 (0.35, 1.11) 12.9 (5.0, 27.7) 0.64 (0.32, 1.28) 0.45 (0.21, 0.93)
CCL5 rs3817655 .74 .60 .40 .52 .12
 A/A 27 12 (55%) 10 (45%) 2.0 (1.8, 3.2) 1 (Reference) 1 (Reference) 7.1 (4.0, 29.9) 1 (Reference) 1 (Reference)
 A/T 34 12 (48%) 13 (52%) 2.0 (1.6, 3.7) 0.87 (0.52, 1.46) 0.98 (0.58, 1.67) 8.7 (4.6, 12.6) 1.00 (0.54, 1.86) 1.28 (0.67, 2.44)
 T/T 18 7 (41%) 10 (59%) 1.9 (1.7, 4.5) 0.75 (0.40, 1.38) 0.67 (0.35, 1.26) 12.9 (5.0, 27.7) 0.68 (0.32, 1.47) 0.57 (0.26, 1.24)
.58 .40 .18 .25 .055
 Any A 61 24 (51%) 23 (49%) 2.0 (1.8, 2.7) 1 (Reference) 1 (Reference) 7.9 (5.8, 11.8) 1 (Reference) 1 (Reference)
 T/T 18 7 (41%) 10 (59%) 1.9 (1.7, 4.5) 0.81 (0.47, 1.39) 0.67 (0.38, 1.19) 12.9 (5.0, 27.7) 0.68 (0.35, 1.34) 0.50 (0.25, 1.02)
CCR5 rs1799988 .019 .25 .50 .43 .55
 T/T 25 5 (25%) 15 (75%) 1.8 (1.1, 2.3) 1 (Reference) 1 (Reference) 6.3 (4.0, 27.2) 1 (Reference) 1 (Reference)
 T/C 29 12 (50%) 12 (50%) 2.3 (1.8, 3.3) 0.65 (0.37, 1.14) 0.71 (0.40, 1.26) 9.6 (5.0, 13.6) 0.88 (0.45, 1.70) 0.88 (0.45, 1.73)
 C/C 24 14 (70%) 6 (30%) 2.7 (1.6, 4.5) 0.74 (0.42, 1.30) 0.80 (0.45, 1.42) 12.6 (6.5, 15.5) 0.64 (0.32, 1.30) 0.68 (0.33, 1.39)
.016 .11 .26 .35 .43
 T/T 25 5 (25%) 15 (75%) 1.8 (1.1, 2.3) 1 (Reference) 1 (Reference) 6.3 (4.0, 27.2) 1 (Reference) 1 (Reference)
 Any C 53 26 (59%) 18 (41%) 2.5 (1.8, 3.3) 0.69 (0.42, 1.12) 0.75 (0.46, 1.23) 10.3 (6.7, 12.9) 0.76 (0.42, 1.38) 0.78 (0.42, 1.44)
.031 .81 .86 .22 .30
 Any T 54 17 (39%) 27 (61%) 2.0 (1.8, 2.3) 1 (Reference) 1 (Reference) 7.8 (5.0, 10.8) 1 (Reference) 1 (Reference)
 C/C 24 14 (70%) 6 (30%) 2.7 (1.6, 4.5) 0.94 (0.58, 1.54) 0.96 (0.58, 1.58) 12.6 (6.5, 15.5) 0.69 (0.38, 1.26) 0.73 (0.40, 1.33)
CCL3 rs1130371 .31 .064 .41 .76 .23
 G/G 36 16 (57%) 12 (43%) 2.5 (1.7, 4.1) 1 (Reference) 1 (Reference) 8.1 (4.6, 12.9) 1 (Reference) 1 (Reference)
 Any A 42 15 (42%) 21 (58%) 2.0 (1.8, 2.4) 1.48 (0.91, 2.39) 1.23 (0.75, 2.01) 9.6 (6.1, 12.9) 1.09 (0.62, 1.90) 0.70 (0.39, 1.26)
CCL4 rs1634517 .12 .12 .14 .13 .17
 C/C 42 20 (57%) 15 (43%) 2.5 (1.7, 3.7) 1 (Reference) 1 (Reference) 8.1 (5.1, 13.6) 1 (Reference) 1 (Reference)
 C/A 26 6 (30%) 14 (70%) 1.9 (1.6, 2.4) 1.60 (0.95, 2.69) 1.67 (1.00, 2.78) 11.8 (7.1, 15.3) 0.89 (0.48, 1.68) 0.79 (0.41, 1.50)
 A/A 9 5 (63%) 3 (38%) 2.0 (0.6, 4.5) 1.40 (0.66, 2.97) 1.35 (0.64, 2.85) 6.1 (1.5, 13.9) 1.96 (0.91, 4.20) 1.76 (0.80, 3.86)
.21 .043 .058 .71 .96
 C/C 42 20 (57%) 15 (43%) 2.5 (1.7, 3.7) 1 (Reference) 1 (Reference) 8.1 (5.1, 13.6) 1 (Reference) 1 (Reference)
 Any A 35 11 (39%) 17 (61%) 2.0 (1.8, 2.4) 1.54 (0.96, 2.50) 1.58 (0.98, 2.53) 9.6 (6.1, 12.9) 1.11 (0.64, 1.94) 0.99 (0.56, 1.74)
KLF13 rs2241779 .62 .21 .019 .57 .20
 C/C 30 14 (56%) 11 (44%) 3.0 (1.8, 4.6) 1 (Reference) 1 (Reference) 10.3 (6.1, 15.5) 1 (Reference) 1 (Reference)
 C/A 33 12 (46%) 14 (54%) 1.8 (1.5, 2.3) 1.48 (0.89, 2.45) 2.13 (1.24, 3.65) 8.1 (5.1, 12.0) 1.37 (0.74, 2.55) 1.78 (0.94, 3.40)
 A/A 15 5 (38%) 8 (62%) 2.0 (1.6, 2.7) 1.49 (0.79, 2.80) 1.83 (0.95, 3.50) 7.9 (3.1, 29.9) 1.32 (0.61, 2.85) 1.54 (0.71, 3.37)
.44 .079 .006 .29 .081
 C/C 30 14 (56%) 11 (44%) 3.0 (1.8, 4.6) 1 (Reference) 1 (Reference) 10.3 (6.1, 15.5) 1 (Reference) 1 (Reference)
 Any A 48 17 (44%) 22 (56%) 1.9 (1.7, 2.3) 1.48 (0.93, 2.36) 2.02 (1.23, 3.33) 7.9 (5.2, 11.8) 1.35 (0.76, 2.40) 1.70 (0.94, 3.07)
CCL5 rs2280789 .55 .27 .17 .29 .42
 A/A 106 38 (37%) 64 (63%) 2.0 (1.8, 2.3) 1 (Reference) 1 (Reference) 5.9 (4.7, 7.8) 1 (Reference) 1 (Reference)
 A/Ga 41 12 (32%) 26 (68%) 2.1 (1.9, 2.8) 0.82 (0.57, 1.19) 0.76 (0.52, 1.12) 8.0 (4.3, 10.1) 0.82 (0.56, 1.20) 0.85 (0.57, 1.26)
 G/Ga 2 0 (0%) 2 (100%)
CCL5 rs3817655 .42 .42 .10 .51 .34
 A/A 98 35 (37%) 60 (63%) 2.0 (1.8, 2.3) 1 (Reference) 1 (Reference) 6.3 (5.0, 7.9) 1 (Reference) 1 (Reference)
 A/Ta 47 15 (32%) 32 (68%) 2.2 (1.9, 2.5) 0.87 (0.62, 1.23) 0.74 (0.51, 1.06) 6.0 (4.3, 9.7) 0.89 (0.62, 1.27) 0.83 (0.57, 1.21)
 T/Ta 4 0 4 (100%)
CCR5 rs1799988 .32 .40 .076 .66 .21
 T/T 52 13 (27%) 36 (73%) 2.1 (1.8, 2.3) 1 (Reference) 1 (Reference) 5.5 (4.0, 7.8) 1 (Reference) 1 (Reference)
 T/C 64 24 (39%) 37 (61%) 2.1 (1.8, 3.7) 0.78 (0.54, 1.13) 0.64 (0.43, 0.94) 8.9 (5.7, 10.5) 0.84 (0.57, 1.24) 0.70 (0.47, 1.04)
 C/C 34 13 (39%) 20 (61%) 1.9 (1.8, 3.4) 0.89 (0.57, 1.37) 0.76 (0.49, 1.18) 5.6 (3.4, 8.7) 0.93 (0.59, 1.47) 0.87 (0.54, 1.40)
.14 .22 .032 .44 .12
 T/T 52 13 (27%) 36 (73%) 2.1 (1.8, 2.3) 1 (Reference) 1 (Reference) 5.5 (4.0, 7.8) 1 (Reference) 1 (Reference)
 Any C 98 37 (39%) 57 (61%) 2.1 (1.8, 2.7) 0.81 (0.58, 1.15) 0.68 (0.48, 0.97) 7.1 (5.1, 9.5) 0.87 (0.61, 1.24) 0.75 (0.52, 1.08)
CCL3 rs1130371 .10 .002 .027 .004 .047
 G/G 95 37 (40%) 55 (60%) 2.3 (2.1, 3.4) 1 (Reference) 1 (Reference) 7.9 (5.9, 9.6) 1 (Reference) 1 (Reference)
 Any A 55 13 (25%) 38 (75%) 1.8 (1.7, 2.0) 1.66 (1.18, 2.33) 1.50 (1.05, 2.15) 4.4 (2.7, 6.4) 1.65 (1.16, 2.34) 1.44 (1.01, 2.07)
CCL4 rs1634517 .077 .003 .040 .004 .034
 C/C 95 37 (41%) 54 (59%) 2.3 (2.1, 3.6) 1 (Reference) 1 (Reference) 7.9 (5.9, 9.6) 1 (Reference) 1 (Reference)
 C/A 48 10 (22%) 35 (78%) 1.8 (1.7, 2.0) 1.73 (1.21, 2.48) 1.58 (1.08, 2.30) 4.9 (2.7, 7.6) 1.56 (1.08, 2.24) 1.37 (0.94, 1.99)
 A/A 7 3 (43%) 4 (57%) 1.7 (0.9, 3.1) 1.78 (0.82, 3.89) 1.72 (0.78, 3.78) 3.4 (1.0, 5.9) 2.67 (1.22, 5.86) 2.53 (1.15, 5.56)
.070 <.001 .012 .004 .041
 C/C 95 37 (41%) 54 (59%) 2.3 (2.1, 3.6) 1 (Reference) 1 (Reference) 7.9 (5.9, 9.6) 1 (Reference) 1 (Reference)
 Any A 55 13 (25%) 39 (75%) 1.8 (1.7, 2.0) 1.74 (1.24, 2.45) 1.59 (1.11, 2.29) 4.4 (2.7, 6.4) 1.65 (1.16, 2.34) 1.46 (1.01, 2.09)
KLF13 rs2241779 .21 .28 .17 .88 .51
 C/C 33 13 (43%) 17 (57%) 2.3 (1.8, 4.1) 1 (Reference) 1 (Reference) 8.0 (3.6, 10.0) 1 (Reference) 1 (Reference)
 A/C 72 19 (28%) 50 (72%) 1.9 (1.8, 2.1) 1.38 (0.91, 2.09) 1.37 (0.90, 2.09) 5.9 (4.5, 7.8) 1.06 (0.69, 1.63) 1.05 (0.68, 1.62)
 A/A 44 17 (40%) 26 (60%) 2.3 (1.9, 2.8) 1.15 (0.73, 1.82) 0.99 (0.62,1.58) 5.7 (4.4, 9.5) 0.96 (0.60, 1.53) 0.83 (0.51, 1.34)
.28 .21 .38 .93 .83
 C/C 33 13 (43%) 17 (57%) 2.3 (1.8, 4.1) 1 (Reference) 1 (Reference) 8.0 (3.6, 10.0) 1 (Reference) 1 (Reference)
 Any A 116 36 (32%) 76 (68%) 2.0 (1.8, 2.3) 1.28 (0.86, 1.90) 1.20 (0.80, 1.78) 5.9 (4.7, 7.8) 1.02 (0.68, 1.52) 0.96 (0.64, 1.44)

Abbreviations: PD = progressive disease; PR = partial response; SD = stable disease.

P values<.05 were shown in bold.

*

P value was based on the Fisher’s exact test for response, log-rank test in the univariate analysis

() and Wald test in the multivariable analysis within Cox regression model

() adjusted for liver metastasis and LN metastasis in the evaluation cohort; time to REGO started (<18 vs ≥18 months), ECOG performance status (0 vs 1 or 2), primary tumor resection (yes vs no), and Kohne score (low-intermediate vs high) in the validation cohort.

a

Grouped together for estimate of HR.